Annual FCF
-$12.36 M
+$3.58 M+22.44%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual free cash flow is -$12.36 million, with the most recent change of +$3.58 million (+22.44%) on March 1, 2024.
- During the last 3 years, GRCE annual FCF has risen by +$2.03 million (+14.13%).
- GRCE annual FCF is now -544.40% below its all-time high of -$1.92 million, reached on February 1, 2010.
Performance
GRCE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$4.24 M
-$643.00 K-17.88%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly free cash flow is -$4.24 million, with the most recent change of -$643.00 thousand (-17.88%) on September 1, 2024.
- Over the past year, GRCE quarterly FCF has dropped by -$2.35 million (-124.05%).
- GRCE quarterly FCF is now -7710.41% below its all-time high of $55.70 thousand, reached on February 1, 2013.
Performance
GRCE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$11.81 M
-$2.13 M-21.94%
September 1, 2024
Summary
- As of February 8, 2025, GRCE TTM free cash flow is -$11.81 million, with the most recent change of -$2.13 million (-21.94%) on September 1, 2024.
- Over the past year, GRCE TTM FCF has increased by +$1.76 million (+12.99%).
- GRCE TTM FCF is now -1366.79% below its all-time high of -$805.50 thousand, reached on May 1, 2009.
Performance
GRCE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
GRCE Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.4% | -124.0% | +13.0% |
| 3 y3 years | +14.1% | -23.2% | +28.8% |
| 5 y5 years | +51.2% | +30.9% | +13.0% |
GRCE Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +28.3% | -124.0% | +32.1% | -21.9% | +38.7% |
| 5 y | 5-year | at high | +51.2% | -140.8% | +42.4% | -21.9% | +59.1% |
| alltime | all time | -544.4% | +51.2% | -7710.4% | +50.3% | -1366.8% | +59.1% |
Grace Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.24 M(+17.9%) | -$11.81 M(+21.9%) |
| Jun 2024 | - | -$3.60 M(+72.2%) | -$9.69 M(-21.4%) |
| Mar 2024 | -$12.36 M(-22.4%) | -$2.09 M(+10.4%) | -$12.33 M(-9.2%) |
| Dec 2023 | - | -$1.89 M(-10.5%) | -$13.58 M(-11.9%) |
| Sep 2023 | - | -$2.11 M(-66.1%) | -$15.41 M(-7.9%) |
| Jun 2023 | - | -$6.24 M(+87.2%) | -$16.74 M(+5.1%) |
| Mar 2023 | -$15.93 M(-7.6%) | -$3.33 M(-10.4%) | -$15.93 M(+1.2%) |
| Dec 2022 | - | -$3.72 M(+8.2%) | -$15.74 M(-5.2%) |
| Sep 2022 | - | -$3.44 M(-36.7%) | -$16.60 M(-13.8%) |
| Jun 2022 | - | -$5.43 M(+72.8%) | -$19.27 M(+11.8%) |
| Mar 2022 | -$17.23 M(+19.8%) | -$3.15 M(-31.4%) | -$17.23 M(+8.7%) |
| Dec 2021 | - | -$4.58 M(-24.9%) | -$15.85 M(+2.4%) |
| Sep 2021 | - | -$6.10 M(+79.5%) | -$15.48 M(+14.0%) |
| Jun 2021 | - | -$3.40 M(+93.2%) | -$13.58 M(-5.6%) |
| Mar 2021 | -$14.39 M(-38.2%) | -$1.76 M(-58.2%) | -$14.39 M(-7.5%) |
| Dec 2020 | - | -$4.21 M(+0.1%) | -$15.56 M(-16.8%) |
| Sep 2020 | - | -$4.21 M(+0.1%) | -$18.71 M(-9.3%) |
| Jun 2020 | - | -$4.21 M(+43.5%) | -$20.63 M(-11.3%) |
| Mar 2020 | -$23.27 M(-8.1%) | -$2.93 M(-60.2%) | -$23.27 M(-19.4%) |
| Dec 2019 | - | -$7.36 M(+20.0%) | -$28.87 M(+1.5%) |
| Sep 2019 | - | -$6.13 M(-10.3%) | -$28.45 M(+2.8%) |
| Jun 2019 | - | -$6.84 M(-19.7%) | -$27.67 M(+9.3%) |
| Mar 2019 | -$25.32 M(+152.0%) | -$8.53 M(+22.8%) | -$25.32 M(+26.0%) |
| Dec 2018 | - | -$6.95 M(+29.8%) | -$20.09 M(+19.9%) |
| Sep 2018 | - | -$5.35 M(+18.9%) | -$16.76 M(+26.9%) |
| Jun 2018 | - | -$4.50 M(+36.3%) | -$13.21 M(+31.4%) |
| Mar 2018 | -$10.05 M(+41.3%) | -$3.30 M(-8.6%) | -$10.05 M(+48.9%) |
| Dec 2017 | - | -$3.61 M(+100.7%) | -$6.75 M(+36.7%) |
| Sep 2017 | - | -$1.80 M(+34.2%) | -$4.93 M(+16.4%) |
| Jun 2017 | - | -$1.34 M(-25.4%) | -$4.24 M(-30.8%) |
| Mar 2017 | -$7.11 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2016 | - | -$1.80 M(+63.0%) | -$6.12 M(+9.1%) |
| Aug 2016 | - | -$1.10 M(-44.4%) | -$5.61 M(-9.8%) |
| May 2016 | - | -$1.98 M(+59.5%) | -$6.22 M(+21.5%) |
| Feb 2016 | -$5.12 M(-12.0%) | -$1.24 M(-3.5%) | -$5.12 M(-9.2%) |
| Nov 2015 | - | -$1.29 M(-24.9%) | -$5.64 M(-9.1%) |
| Aug 2015 | - | -$1.71 M(+94.8%) | -$6.21 M(-0.4%) |
| May 2015 | - | -$879.70 K(-50.0%) | -$6.23 M(+7.0%) |
| Feb 2015 | -$5.82 M(-6.8%) | -$1.76 M(-4.9%) | -$5.82 M(-29.6%) |
| Nov 2014 | - | -$1.85 M(+6.5%) | -$8.26 M(+13.7%) |
| Aug 2014 | - | -$1.74 M(+270.4%) | -$7.27 M(+25.6%) |
| May 2014 | - | -$469.60 K(-88.8%) | -$5.79 M(-7.4%) |
| Feb 2014 | -$6.25 M(+141.2%) | -$4.20 M(+391.8%) | -$6.25 M(+214.0%) |
| Nov 2013 | - | -$854.70 K(+230.9%) | -$1.99 M(+15.1%) |
| Aug 2013 | - | -$258.30 K(-72.3%) | -$1.73 M(-40.2%) |
| May 2013 | - | -$933.00 K(-1775.0%) | -$2.89 M(+11.6%) |
| Feb 2013 | -$2.59 M(-54.1%) | $55.70 K(-109.4%) | -$2.59 M(-36.5%) |
| Nov 2012 | - | -$593.60 K(-58.2%) | -$4.08 M(-38.5%) |
| Aug 2012 | - | -$1.42 M(+124.8%) | -$6.63 M(+13.3%) |
| May 2012 | - | -$631.90 K(-55.9%) | -$5.85 M(+3.7%) |
| Feb 2012 | -$5.65 M(+191.7%) | -$1.43 M(-54.4%) | -$5.65 M(+25.0%) |
| Nov 2011 | - | -$3.14 M(+387.7%) | -$4.52 M(+72.5%) |
| Aug 2011 | - | -$644.80 K(+51.6%) | -$2.62 M(+17.8%) |
| May 2011 | - | -$425.20 K(+39.9%) | -$2.22 M(+14.9%) |
| Feb 2011 | -$1.94 M(+1.0%) | -$303.90 K(-75.6%) | -$1.94 M(+0.3%) |
| Nov 2010 | - | -$1.25 M(+399.0%) | -$1.93 M(+51.3%) |
| Aug 2010 | - | -$249.70 K(+83.1%) | -$1.28 M(+3.5%) |
| May 2010 | - | -$136.40 K(-54.4%) | -$1.23 M(-35.2%) |
| Feb 2010 | -$1.92 M | -$298.90 K(-49.5%) | -$1.90 M(+18.6%) |
| Nov 2009 | - | -$591.30 K(+186.6%) | -$1.60 M(+58.4%) |
| Aug 2009 | - | -$206.30 K(-74.4%) | -$1.01 M(+25.6%) |
| May 2009 | - | -$805.50 K | -$805.50 K |
FAQ
- What is Grace Therapeutics annual free cash flow?
- What is the all time high annual FCF for Grace Therapeutics?
- What is Grace Therapeutics annual FCF year-on-year change?
- What is Grace Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Grace Therapeutics?
- What is Grace Therapeutics quarterly FCF year-on-year change?
- What is Grace Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Grace Therapeutics?
- What is Grace Therapeutics TTM FCF year-on-year change?
What is Grace Therapeutics annual free cash flow?
The current annual FCF of GRCE is -$12.36 M
What is the all time high annual FCF for Grace Therapeutics?
Grace Therapeutics all-time high annual free cash flow is -$1.92 M
What is Grace Therapeutics annual FCF year-on-year change?
Over the past year, GRCE annual free cash flow has changed by +$3.58 M (+22.44%)
What is Grace Therapeutics quarterly free cash flow?
The current quarterly FCF of GRCE is -$4.24 M
What is the all time high quarterly FCF for Grace Therapeutics?
Grace Therapeutics all-time high quarterly free cash flow is $55.70 K
What is Grace Therapeutics quarterly FCF year-on-year change?
Over the past year, GRCE quarterly free cash flow has changed by -$2.35 M (-124.05%)
What is Grace Therapeutics TTM free cash flow?
The current TTM FCF of GRCE is -$11.81 M
What is the all time high TTM FCF for Grace Therapeutics?
Grace Therapeutics all-time high TTM free cash flow is -$805.50 K
What is Grace Therapeutics TTM FCF year-on-year change?
Over the past year, GRCE TTM free cash flow has changed by +$1.76 M (+12.99%)